股腘动脉原发病变腔内治疗方式的网状Meta分析
该网状Meta分析纳入45项随机对照试验(5565例患者),比较14种腔内治疗对股腘动脉原发病变的效果。结果显示药物洗脱支架(DES)和覆膜支架(CS)在再狭窄和靶病变血运重建(TLR)方面优势显著,DES在12个月内表现更佳,CS在约24个月时更优,但两者对死亡率无显著优势;冷冻成形术效果较差。
要点
- DES和CS在股腘动脉原发病变的再狭窄和TLR方面优于多数其他单药治疗。
- DES在6和12个月随访时再狭窄和TLR效果最佳,CS在24个月时再狭窄和TLR效果最佳。
- DES和CS的12个月全因死亡率与其他治疗相似,冷冻成形术再狭窄和TLR效果最差。
核心结论
- DES和CS在股腘动脉原发病变的再狭窄和TLR方面具有显著优势,技术成功率与聚合支架技术相似。
- DES在术后12个月内表现更优,CS在约24个月时更优,但两者对死亡率均无明显优势。
- 冷冻成形术在再狭窄和TLR方面效果较差。
研究设计与样本
- 网状Meta分析,系统检索MEDLINE、EMBASE和Cochrane Central Register of Controlled Trials数据库(截至2019年6月1日)。
- 纳入比较14种腔内治疗(包括斑块旋切、近距离放疗、冷冻成形、切割球囊、药物涂层球囊、裸镍钛支架、药物洗脱支架、覆膜支架及组合)治疗股腘动脉原发病变的前瞻性随机对照试验。
- 最终纳入53篇文章报道的45项研究(91个研究臂;5565例患者)。
主要发现
- 技术成功率方面,聚合支架技术最有效,优于球囊和斑块旋切技术。
- 再狭窄方面,DES在6和12个月随访时最有效,CS在24个月随访时最有效;DES和CS均优于多数其他单药治疗(包括球囊血管成形、切割球囊、冷冻成形、定向斑块旋切和裸镍钛支架)。
- TLR方面,DES在6和12个月随访时最有效,CS在24个月随访时最有效;DES和CS均优于多数其他单药治疗。
- 12个月全因死亡率方面,DES和CS与其他治疗相似;冷冻成形术在再狭窄和TLR方面效果最差。
临床怎么用
- 对于股腘动脉原发病变,可优先考虑DES(12个月内)或CS(约24个月)以降低再狭窄和TLR风险。
- 冷冻成形术在再狭窄和TLR方面效果较差,临床选择时需权衡。
- DES和CS对12个月全因死亡率无显著影响,决策时应结合其他临床因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To report the results of a network meta-analysis of randomized controlled trials (RCTs) comparing multiple endovascular treatments for de novo femoropopliteal lesions. Materials and Methods: The MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials databases were systematically searched on June 1, 2019, for prospective RCTs comparing 14 treatments [ie, atherectomy, brachytherapy, cryoplasty, cutting balloons, drug-coated balloons, bare nitinol stents, drug-eluting stents (DES), covered stents (CS), and combinations] in the treatment of de novo femoropopliteal lesions. Outcomes were technical success; binary restenosis and target lesion revascularization (TLR) at 6, 12, and/or 24 months; and all-cause mortality at 12 months. Ultimately, 53 articles reporting on 45 studies (91 study arms; 5565 patients) were selected. For the technical success outcome, all types of stents, all balloons, and all atherectomy devices were aggregated in stent, balloon, and atherectomy technology groups, respectively. Results: In terms of technical success for aggregated treatment types, stent technology was the most effective treatment and was better than balloon and atherectomy technologies. In terms of binary restenosis, DES was the most effective single treatment at the 6- and 12-month follow-up and CS at the 24-month follow-up. Both DES and CS were better than the majority of other single treatments, including balloon angioplasty, cutting balloon, cryoplasty, directional atherectomy, and bare nitinol stent during all follow-up periods. In terms of TLR, DES was the second most effective single treatment and the most effective single treatment at the 6- and 12-month follow-up intervals; CS was the most effective single treatment at the 24-month follow-up. Both DES and CS were better than the majority of other single treatments. The 12-month all-cause mortality of both DES and CS were similar to other treatments, whereas cryoplasty seemed to be the least effective treatment with regard to binary restenosis and TLR. Conclusion: Both DES and CS had substantial advantages in terms of restenosis and TLR in femoropopliteal lesions and were similar to aggregate stent technology in terms of technical success. DES performed better within 12 months after operation and CS at ~24 months, but neither had much advantage in terms of mortality. In contrast, cryoplasty seemed to be a less effective treatment.
引用
- Zhou Y, Zhang Z, Lin S, et al. Comparative Effectiveness of Endovascular Treatment Modalities for De Novo Femoropopliteal Lesions: A Network Meta-analysis of Randomized Controlled Trials. J Endovasc Ther. 2020. PMID: 31948375. doi:10.1177/1526602819895996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。